Scientists from Massachusetts Institute of Technology (MA, USA) have developed a urine test that can identify proteins associated with lung cancer. It is hoped the nanoparticle-based test could reduce the quantity of false positives and improve early detection.
Researchers from Mologic Ltd (Bedford, UK) have announced that they are currently validating a COVID-19 diagnostic test with the Liverpool School of Tropical Medicine (UK), St Georges’ University (London, UK).
To provide remote support for sites and patients enrolled in clinical trials, PRA Health Sciences (NC, USA) has expanded its mobile health platform. New capabilities could help to address sponsor needs for virtual support during the global COVID-19 pandemic.
Scientists from New York University Abu Dhabi (UAE) have developed a new microfluidic platform compatible with atomic force microscopy that could be used to perform liquid cancer biopsies. The tool could also be used to identify new metastatic mechano-biomarkers.
PRA Health Sciences (NC, USA), a North Carolina-based CRO, has announced the commercial availability of a COVID-19 monitoring program. The program, a mobile app-based initiative will track the health of individuals during the COVID-19 pandemic.
A joint study conducted by researchers from the University of the Ryukyus (Nishihara, Japan) and NEC Corporation (Tokyo, Japan) has identified a novel diagnostic biomarker for acute adult T-cell leukemia/lymphoma.
The US FDA has granted emergency use authorization for coronavirus assays from Hologic (MA, USA) and Labcorp (NC, USA). The assays will join those provided by Roche (Basel, Switzerland) and Thermo Fisher Scientific (MA, USA).
The US FDA has issued an emergency use authorization for a Thermo Fisher Scientific (MA, USA) diagnostic test that can be used to detect nucleic acid from SARS-CoV-2, the virus responsible for COVID-19.
Thermo Fisher Scientific (MA, USA) and Janssen Biotech (PA, USA) have entered an agreement to co-develop an oncology companion diagnostic. The companion diagnostic will be designed to support global clinical trial enrolment.
QPS Holdings LLC (DE, USA), a global CRO, have announced an access restricted bioanalysis lab that is set up to analyze clinical trial samples for treatments and vaccines to combat the novel coronavirus, COVID-19.